A HER2-targeted antibody–drug conjugate composed of a humanized anti‑HER2 monoclonal antibody linked via an enzyme‑cleavable linker to a topoisomerase I inhibitor payload; binding to HER2 (ERBB2) leads to internalization and intracellular release of the cytotoxic payload, inducing DNA damage and tumor cell death with potential bystander effect.
HER2-directed antibody-drug conjugate: a humanized anti-HER2 antibody binds ERBB2 on tumor cells, is internalized, and an enzyme-cleavable linker releases a topoisomerase I (Topo I) inhibitor payload intracellularly, inhibiting Topo I to cause DNA damage, cell-cycle arrest, apoptosis, and potential bystander killing.
The ADC binds HER2 (ERBB2), is internalized, and releases a topoisomerase I inhibitor via a cleavable linker, causing DNA damage, cell-cycle arrest, and apoptosis in HER2-expressing cells (with potential bystander effect).
Rabbit polyclonal antilymphocyte globulin used for in vivo T-cell depletion to reduce graft-versus-host disease risk.
Rabbit polyclonal IgG against multiple human T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, HLA) that depletes T lymphocytes via complement-dependent cytotoxicity, Fc-mediated ADCC/phagocytosis, and apoptosis, producing in vivo T‑cell immunosuppression to reduce GVHD risk.
rATG contains antibodies to HLA class I; binding to HLA‑B on cells triggers complement-dependent lysis and Fc-mediated ADCC/phagocytosis, causing cell death.
Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.
ATG antibodies bind CD2 on T cells, activating complement for lysis and engaging Fcγ receptor–bearing effector cells to mediate ADCC and phagocytosis, depleting CD2+ cells.
Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.
ATG binds CD3 on T cells and induces complement-dependent lysis and Fc-mediated ADCC/phagocytosis, depleting CD3+ cells.
Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.
Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.
ATG binds CD4 on T cells and depletes them via complement-dependent lysis and Fc-mediated ADCC/antibody-dependent phagocytosis.